Pressurized intrathoracic aerosol chemotherapy (PITAC) for malignant pleural mesothelioma—ex vivo evaluation of optimal treatment conditions and comparison with hyperthermic intrathoracic chemotherapy (HITOC) Authors: Katharina Flöthmann, Norman Zinne, Peter Braubach, Alina Meininger, Imke Becker, Nicole Ernst, Arjang Ruhparwar, Hayan Merhej, Patrick Zardo Published: 2026 ABSTRACT AbstractBackgroundMalignant pleural mesothelioma (MPM) is a rare but aggressive disease with poor prognosis and limited treatment options. Pressurized intrathoracic aerosol chemotherapy (PITAC) has emerged as a novel approach for intrathoracic drug delivery. The aim of this study was to investigate cisplatin penetration characteristics and to evaluate procedural parameters influencing drug penetration, including temperature, drug concentration and pleural barrier function, in an ex vivo model. In addition, PITAC was compared with hyperthermic intrathoracic chemotherapy (HITOC), a treatment modality applied in selected specialized centers as part of multimodal treatment concepts for MPM.MethodsWe investigated the penetration depth and intensity of aerosolized cisplatin generated using a high-pressure nebulizer in an ex vivo setting. Potential influencing factors, including temperature, cisplatin concentration and barrier function of the pleura, were gradually modified, as we sought to evaluate optimal procedural conditions. Finally, PITAC was compared with a previously standardized HITOC approach.ResultsA temperature of 42 ℃, a cisplatin concentration of 1 mg/mL, and prior removal of the pleura, improved the penetration depth and intensity of the chemotherapeutic agent. Under clinically relevant experimental conditions, aerosolized cisplatin application demonstrated greater tissue penetration compared to HITOC.ConclusionsOur preclinical data suggest that PITAC may be a viable alternative to HITOC and warrants further clinical investigation.Keywords: Pressurized intraperitoneal aerosol chemotherapy (PIPAC), pressurized intrathoracic aerosol chemotherapy, mesothelioma, hyperthermic intrathoracic chemotherapy (HITOC) Highlight box Key findings • Aerosol based chemotherapy may constitute a viable approach in mesothelioma. What is known and what is new? • Pressurized intraperitoneal aerosol chemotherapy has been introduced into clinical practice for mesothelioma treatment, but clinical evidence for intrathoracic application is very limited. • Our preclinical data suggests that this approach may be viable for pleural mesothelioma as well. What is the implication, and what should change now? • We suggest to further explore pressurized intrathoracic aerosol chemotherapy in clinical settings. Introduction Malignant mesothelioma (MM) is a rare but extremely aggressive tumour originating from mesothelial cells (1). More than 80% of MM cases occur as malignant pleural mesothelioma (MPM) and its pathogenesis is closely associated with asbestos exposure (2). Although the use of asbestos has been prohibited in Germany since 1993, it is assumed that the peak incidence of MPM is still to occur, as tumours appear with a latency period of up to 50 years (3). It can be histologically classified into three subtypes (epithelioid, sarcomatoid and biphasic), with the epithelioid form having the most favorable prognosis (4). Due to nonspecific symptoms such as persistent cough or dyspnea, the diagnosis is often made at an advanced stage. With a median overall survival of 12–36 months for localized and 8–14 months for advanced disease, the prognosis for MM remains poor despite novel therapeutic approaches, including monoclonal antibodies (3,5,6). This is due not only to an advanced stage of the tumour upon diagnosis, but also to a generally poor response to systemic immuno- and/or chemotherapy. Currently, most curative treatment approaches are centered around trimodal concepts including surgical resection, immunochemotherapy and irradiation, although results from a recent phase 3 trial generally appear to discourage any form of surgical intervention (7). Surgical practice has shifted from more radical approaches like P3D (Pleuro-pneumonectomy with pericardial and diaphragm resection) towards pleurectomy and decortication (P/D), which is based on removing all macroscopically detectable tumor tissue to obtain macroscopic complete resection (MCR). Selected centers additionally perform hyperthermic intrathoracic chemotherapy (HITOC) as an adjunct to cytoreductive surgery, to deliver heated chemotherapy directly into the pleural cavity as a means to enhance local drug concentrations and cytotoxicity while minimizing systemic side effects (4,8). Pressurized intrathoracic aerosol chemotherapy (PITAC) is a novel technique of applying chemotherapeutic drugs by generating an aerosol via a high-pressure nebulizer, and has already been anecdotally reported in MPM (9). Compared to HITOC, PITAC may allow for even higher local active drug concentrations at a fraction of the cumulative doses, thus even further reducing the risk of systemic side effects. Initial studies have demonstrated its clinical feasibility in malignant pleural effusion (MPE) (10), and first reports of significant tumour reduction up to complete regression have been described in peritoneal metastases treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC) (11-13). These findings prompted us to further evaluate PITAC in MPM, and investigate its ideal conditions in a preclinical ex vivo model. Furthermore, we compared aerosol application with HITOC, a treatment modality applied in selected specialized centers as part of multimodal treatment concepts for MPM. In addition, prior experimental studies have predominantly focused on the peritoneal surface, without assessing drug penetration into deeper tissue layers. However, these layers are of particular relevance in MPM, as tumour growth is not limited to the surface but also extends into underlying structures. Therefore, the present study was designed to evaluate cisplatin penetration not only in the pleura but also in deeper tissue layers, including connective tissue and muscle. We present this article in accordance with the ARRIVE reporting checklist (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-1-0258/rc). Methods Study design This ex vivo study aimed to compare the drug penetration depth and intensity between HITOC and PITAC in porcine intercostal muscles. In addition, we investigated various parameters that may influence the penetration depth and intensity of cisplatin to evaluate the most effective approach for clinical use. Analyzed parameters The following variables were evaluated in both HITOC and PITAC settings: Temperature, cisplatin concentration and barrier function of the pleura. Each parameter was independently analyzed by modifying only one variable at a time. Standard conditions were as follows: temperature 42 ℃, cisplatin concentration 1mg/ml and application in aerosolized form with intact pleura. Experimental protocol Samples of porcine intercostal muscle with parietal pleura were collected 30 minutes post mortem. To prevent lateral penetration of the chemotherapeutic agent during cisplatin application, adjacent ribs and epidermal lining were initially left in place during treatment and removed afterwards. During application, the samples were fixed onto polystyrene blocks using needles. To avoid falsification due to local cisplatin accumulation, the samples were fixed as evenly as possible, and the size of the polystyrene was matched to the sample to allow excess liquid to drain off. Samples were placed in a sealed box with an opening for the catheter at a distance of 8 cm from each other. To simulate the shape of the thorax as realistically as possible and to investigate an even distribution of the aerosol within the thorax, we positioned samples on the floor, on the four walls and on the lid of the box. The desired drug temperature was pre-set in a laboratory heating cabinet. Cisplatin was administered at 4.8 bar pressure using a high-pressure injector (Nexus 2000, Chemyx, Stafford, TX, USA) and dedicated syringes, with a total volume of 50 mL per sample, at a controlled injection flow rate of 40 mL/min to ensure stable aerosol generation throughout the application period. Drug concentration and temperature varied depending on the parameters analyzed. After the desired incubation period, all excess material was removed. In the HITOC group, samples were attached to a stand using wires so that they could be adjusted in height to ensure that only the surface of the samples was covered with cisplatin. A roller pump (Typ 2T, Stöcker Instrumente GmbH, Munich, Germany) maintained a consistent temperature and gentle fluid circulation to closely mimic clinical conditions. Continuous circulation of the perfusate ensured homogeneous mixing of the heated cisplatin solution and thereby maintained temperature uniformity throughout the experimental container during the entire exposure period. Suction took place at the front of the bowl and the heated liquid was returned at the back at a flow rate of 0.5 L/min. The total volume in the bowl was 900 mL. Temperature was set at 42 ℃. The tissue samples were exposed to the heated cisplatin perfusate for a total duration of 60 minutes, corresponding to the exposure time commonly used in clinical HITOC protocols. Trials were conducted using two different cisplatin concentrations: 1 mg/mL, representing the maximum pharmacologically possible concentration before precipitation occurs, and 0.125 mg/mL, which corresponds to clinically applicable concentrations. This concentration was selected based on clinical recommendations that limit the total cisplatin dose to 225 mg/m2 body surface area (BSA) in order to minimize systemic toxicity (14). Given that MPM predominantly affects men—approximately four times more often than women—a male patient with an average BSA of 1.9 m2 would reach a maximum total dose of 427.5 mg. Assuming a perfusion volume of 4 liters, which reflects standard clinical practice in HITOC procedures (14), this corresponds to a concentration of approximately 0.125 mg/mL. Therefore, this value represents the highest clinically justifiable concentration in the HITOC setting. Both concentrations were evaluated under the conditions of either preserved or surgically removed pleura. In the ex vivo model, however, the experimentally relevant variable is the drug concentration in mg/ml rather than a patient-specific dose based on BSA. The BSA calculation was therefore used only to translate clinically applied HITOC dosing into an equivalent experimental concentration. The experimental container (900 mL) was selected to approximate the intrathoracic volume and allow standardized experimental conditions, but it was not intended to reproduce the pleural surface area of a patient or to represent a BSA-equivalent system. Cisplatin detection Samples were processed as formalin-fixed, paraffin-embedded (FFPE) sections. Sections were deparaffinized in xylene (2× 10 min) and rehydrated in a descending ethanol series. Heat-induced epitope retrieval was performed using Tris-EDTA buffer (pH 9.0) in a water bath at 96 ℃ for 20 minutes, followed by cooling in ice-cold distilled water (0 ℃) for 5 minutes. Slides were then rinsed three times for 2 minutes each with IHC wash buffer (Medac GmbH, Wedel, Germany). To prevent non-specific antibody binding, sections were incubated with AK-Dilution Medium (100–200 µL per slide; Medac GmbH, Wedel, Germany) for 10 minutes. All subsequent steps were performed in a humidified chamber. Sections were incubated with the primary rat-specific monoclonal antibody R-C18 (Oncolyze GmbH, Essen, Germany), at a 1:500 dilution in AK-Dilution Medium (100 µL per slide) for 40 minutes at room temperature, followed by rinsing with IHC wash buffer (3× 2 min). Staining was performed using a horseradish peroxidase (HRP)-based reaction with DAB530 (Zytomed Systems GmbH, Berlin, Germany) for 10 minutes (200 µL per slide). Sections were placed in distilled water (2× 5 min), stained with undiluted Tinto Hematoxylin (Medac GmbH, Wedel, Germany) for 10 seconds, and subsequently blued in IHC wash buffer (10 min). Dehydration in a series of ascending ethanol concentration (70% for 15 sec, 96 and 100% for 5 min each) and three xylene changes for 5 min each were performed. Subsequent coverings were performed with Eukitt medium and coverlips (15). Microscopic evaluation Ten samples were examined in each experiment. The evaluation of cisplatin efficacy was based not on the staining intensity, but on the extent of DNA adduct formation. Cisplatin exerts its cytotoxic effect by cross-linking adjacent guanine bases within the DNA strands. Guanine adducts were visualized using specific immunohistochemical staining. The identification of pleura, connective tissue and muscular layers was based on the morphological characteristics of the respective tissue structures in the histological sections. All stained samples were evaluated in comparison with the corresponding negative control sections to ensure reliable identification of specific cisplatin-induced DNA adduct staining. DNA adduct staining in the pleura and connective tissue was evaluated using a semi-quantitative scale from 0 to 3, with 0 indicating no detectable DNA adducts, 1 indicating sporadic staining (1–30%, Figure 1), 2 indicating moderate staining (30–60%, Figure 2), and 3 representing extensive staining (60–100%, Figure 3). All ten samples per group were evaluated using this scale, and an average score was calculated. Penetration depth into the muscular tissue was assessed using two parameters: first, by counting the number of individual muscle layers that exhibited positive staining, and second, by assigning an intensity score for staining within those muscular layers, using the same 0–3 scale as described above. For both measures, a mean value across all ten samples was determined. To evaluate the samples, each sample was compared with the corresponding negative control. Histological section of pleural tissue showing sporadic DNA adduct staining (score 1, 1–30% of cells positive). Histological section of pleural tissue showing moderate DNA adduct staining (score 2, 30–60% of cells positive). Histological section of pleural tissue showing extensive DNA adduct staining (score 3, 60–100% of cells positive). Ethical statement Domestic pigs (Sus scrofa forma domestica) aged 10–15 weeks with a body weight of 42±7 kg were used for organ explant procurement. Porcine intercostal muscle specimens with parietal pleura were obtained post mortem from animals euthanized within the framework of an independent research project and not specifically for the present study. No additional animals were sacrificed for this investigation. The original animal procedures and organ explant procurement were approved by the Lower Saxony State Office for Consumer Protection and Food Safety (LAVES; Niedersächsisches Landesamt für Verbraucherschutz und Lebensmittelsicherheit) under approval number 21/3782. As only post-mortem tissue samples were used in this ex vivo study, no additional ethical approval was required for the present experiments. Statistical analysis Data was collected and analyzed in a standard Microsoft® Excel® 2010 spreadsheet and expressed as mean ± standard deviation (SD) after ascertaining normal distribution via modified Kolmogorov-Smirnov-Test. Results Temperature Temperatures of 20 ℃ (room temperature), 36 ℃ (body temperature) and 42 ℃ at a cisplatin concentration of 1 mg/mL were compared and results are presented in Table 1. Cisplatin was administered in aerosol form with the pleura remaining intact. A higher penetration depth was observed with an increase in temperature. The difference between 20 and 36 ℃ was greater than that between 36 and 42 ℃ (Figure 4). Table 1Effect of temperature on aerosolized cisplatin penetration (concentration 1 mg/mL with intact pleura)TemperaturePleuraConnective tissueMuscle layersMuscle intensity20 ℃210011001100120022002200110022002100110036 ℃220010002200210021003321220021003200330042 ℃2200221133001000210033311000336222002200 Effect of temperature on aerosolized cisplatin penetration (concentration 1 mg/mL with intact pleura) Effect of temperature on aerosolized cisplatin penetration (concentration 1 mg/mL with intact pleura). At 20 ℃, mean staining scores were 1.5 in the pleura and 1.4 in the connective tissue. No staining was observed in the muscle layer. At 36 ℃, mean values increased to 2.2 in the pleura and 1.7 in the connective tissue; a mean of 0.2 muscle layers were stained with an intensity score of 0.1. At 42 ℃, pleural staining remained at 2.1, while the connective tissue showed a further increase to 1.8. The number of stained muscle layers increased to a mean of 1.0, with an intensity score of 0.4. Cisplatin concentration To evaluate the effect of cisplatin concentration on tissue penetration, aerosolized cisplatin was applied at concentrations of 0.25, 0.5, and 1.0 mg/mL. All experiments were conducted under standardized conditions, including pleural removal and a temperature of 42 ℃ (Table 2). Table 2´Effect of drug concentration on aerosolized cisplatin penetration (temperature 42 ℃ with removed pleura)Cisplatin concentrationConnective tissueMuscle layersMuscle intensity0.25 mg/mL1312110003002003211003332000.5 mg/mL3821002001001001003430002111 mg/mL3633332111413633003003832122200 ´Effect of drug concentration on aerosolized cisplatin penetration (temperature 42 ℃ with removed pleura) At 0.25 mg/mL, the mean staining score in the connective tissue was 1.9, with 1.0 muscle layer stained and a mean intensity score of 0.7. Increasing the concentration to 0.5 mg/mL resulted in a connective tissue score of 1.6, with 1.4 muscle layers affected and an intensity score of 0.7. At 1.0 mg/mL, the highest applicable concentration before precipitation occurred, the mean connective tissue staining further increased to 2.5, with 4.0 muscle layers involved and a mean intensity score of 1.6. These findings demonstrate a clear, concentration-dependent increase in both penetration depth and staining intensity (Figure 5). Effect of drug concentration on aerosolized cisplatin penetration (temperature 42 ℃ with removed pleura). Barrier function of the pleura Trials were performed with the pleura either preserved or previously removed, using a cisplatin concentration of 1 mg/mL and a temperature of 42 ℃ (Table 3). Table 3Effect of the pleura as a barrier function on cisplatin penetration (temperature 42 ℃ and concentration 1 mg/mL)Barrier function of the pleuraPleuraConnective tissueMuscle layersMuscle intensityPITAC intact pleura2200221133001000210033311000336222002200PITAC removed pleura03630333021101410363030003000383021220200HITOC intact pleura3321334133003362320033102331023310333213321HITOC removed pleura00103001030031002100210021004200103001100123HITOC, hyperthermic intrathoracic chemotherapy; PITAC, pressurized intrathoracic aerosol chemotherapy. Effect of the pleura as a barrier function on cisplatin penetration (temperature 42 ℃ and concentration 1 mg/mL) HITOC, hyperthermic intrathoracic chemotherapy; PITAC, pressurized intrathoracic aerosol chemotherapy. In the aerosol group, preservation of the pleural layer yielded a mean staining score of 2.1 in the pleura and 1.8 in the underlying connective tissue. On an average, 1.0 muscle layers were stained with an intensity score of 0.4. Following pleural removal, staining in the connective tissue increased to a mean score of 2.5, with 4.0 muscle layers stained and an intensity score of 1.6. In the HITOC group, samples with intact pleura showed a mean pleural staining score of 3.0 and a connective tissue score of 2.9. A mean of 4.6 muscle layers were stained, with an intensity score of 1.3. Since the connective tissue was no longer present, and most likely removed together with the pleura, it could not be evaluated; 5.6 muscle layers were stained with a mean intensity score of 1.9. Across both application methods, pleural removal consistently resulted in a greater penetration depth and higher staining intensity (Figure 6). Effect of the pleura as a barrier function on cisplatin penetration (temperature 42 ℃ and concentration 1 mg/mL). HITOC, hyperthermic intrathoracic chemotherapy; PITAC, pressurized intrathoracic aerosol chemotherapy. PITAC versus HITOC To simulate clinically relevant conditions, the performance of both PITAC and HITOC was evaluated using concentrations that correspond to the current clinical standards. Owing to the large perfusate volumes required and the resulting systemic toxicity HITOC is typically performed with cisplatin concentrations of approximately 0.125 mg/mL. In contrast, aerosol application (PITAC) allows for the use of the pharmacological maximum of 1 mg/mL, as the required application volumes are significantly lower. All experiments were conducted at a temperature of 42 ℃ (Table 4). Table 4Effect of the application methods PITAC and HITOC on cisplatin penetration (temperature 42 ℃ and concentration 1 mg/mL)PITAC vs. HITOCConnective tissueMuscle layersMuscle intensityPITAC 1 mg/mL3633332111413633003003832122200HITOC 1 mg/mL321341300362200310231023103321321HITOC 0.125 mg/mL100100100100100100100262221311HITOC, hyperthermic intrathoracic chemotherapy; PITAC, pressurized intrathoracic aerosol chemotherapy. Effect of the application methods PITAC and HITOC on cisplatin penetration (temperature 42 ℃ and concentration 1 mg/mL) HITOC, hyperthermic intrathoracic chemotherapy; PITAC, pressurized intrathoracic aerosol chemotherapy. PITAC at 1 mg/mL resulted in a penetration score of 2.5 in the connective tissue, with an average of 4.0 muscle layers stained and an intensity score of 1.6. At the same concentration, HITOC achieved a higher connective tissue score of 2.9 and a penetration depth of 4.6 muscle layers with an intensity score of 1.3. However, this concentration cannot be used in clinical HITOC settings because of the toxicity concerns associated with the required perfusion volume (12). When applying clinically feasible concentrations, HITOC at 0.125 mg/mL achieved only a mean connective tissue score of 1.4, with an average of 0.9 muscle layers stained and an intensity score of 0.4. Under clinically relevant conditions, PITAC demonstrated superior penetration depth and staining intensity compared with HITOC (Figure 7). Effect of the pleura as a barrier function on cisplatin penetration (temperature 42 ℃ with removed pleura). HITOC, hyperthermic intrathoracic chemotherapy; PITAC, pressurized intrathoracic aerosol chemotherapy. Discussion Despite modern multimodal treatment strategies, primary MPM remains a disease with limited treatment options and a poor prognosis (5,6,15). It hardly responds to systemic chemotherapy, and its laminar growth often makes a complete oncological resection unfeasible (16). Even trimodal approaches combining neoadjuvant chemotherapy, radical surgery including an extrapleural pneumonectomy, pericardiectomy and diaphragm resection, with adjuvant irradiation have yielded unsatisfactory results with high rates of relapse (17-21). Given comparable overall and disease-free survival rates, reduced intraoperative complications and better quality of life, cytoreductive lung-sparing surgery has become the standard of care (22-27). While results from the recent MARS2 trial have raised questions regarding the role of surgery in mesothelioma management (7), it can currently still be considered a mainstay of multimodal treatment concepts. Unlike in both treatment arms of MARS2, certain groups perform intraoperative HITOC after initial MCR to circumvent poor response to systemic therapy, which seems to yield better overall results, especially in epithelioid MPM (28). However, HITOC is technically challenging, requires very high doses of cytostatic drugs and is not suitable for every patient. Pressurized aerosol chemotherapy represents a new technique for intraoperative application of chemotherapeutic agents. By generating a fine aerosol via a high-pressure nebulizer, this method promises a more even drug distribution and, owing to the pressure gradient, an equalisation of the tumour interstitial fluid pressure, which is an obstacle in cancer therapy (29). Solass et al. demonstrated a more even distribution and greater penetration depth using a capnoperitoneum compared to conventional lavage in both an ex vivo model and an in vivo large animal model (11,30). However, these trials were conducted intraperitoneally, and comparable trials for the thoracic cavity have not yet been published. Furthermore, instead of chemotherapeutic drugs, the DNA repair inhibitor Dbait (a nontoxic agent) and methylene blue were investigated, which may behave differently from cytostatic drugs. While they only compared two different drug delivery forms (aerosolized and lavage), we were able to show that other factors, especially the chemotherapeutic drug concentration, play a significant role in penetration depth and intensity. In subsequent trials of end-stage peritoneal carcinomatosis, the same group demonstrated superior pharmacological properties of aerosolized chemotherapy, including higher local drug concentrations and reduced systemic exposure. Among the three patients treated, two showed complete tumor regression and one showed partial tumor regression (11). Encouraged by these initial findings, PIPAC was administered to the first patients with malignant peritoneal mesothelioma (12). In this cohort of 29 patients, 20 received more than two PIPAC treatments and biopsies were performed to assess the histological tumour regression grade (TRG). Tumour regression was observed in 75% of patients, with major or complete regression achieved in 20%. While these results appear encouraging, MPM treatment differs from that for abdominal Mesothelioma, limiting the direct transferability of these findings. In the referenced study, patients did not receive prior cytoreductive surgery, but only repeated PIPAC treatments. Dense adhesions and mandatory pleurectomy prior to potentially implementing PITAC would certainly hinder multiple PITAC applications. Nevertheless, our study suggests that PITAC appears to be superior to HITOC, even in a single application. Higher penetration depths were achieved with PITAC, despite using lower absolute doses. Most notably, PITAC offers a substantial pharmacological advantage: Unlike HITOC, which requires large perfusion volumes and is therefore limited in the maximum applicable drug concentration due to systemic toxicity, PITAC is based on aerosolized delivery using significantly lower total volumes. This permits the administration of the pharmacological maximum cisplatin concentration (1 mg/mL) while maintaining systemic safety (11). Our experiments identified drug concentration as the most influential variable affecting tissue penetration depth and staining intensity. The ability of PITAC to safely deliver higher local drug concentrations may therefore represent a key factor contributing to its potential therapeutic advantage. However, in addition to penetration depth and staining intensity, the spatial distribution of the chemotherapeutic agent within the treated tissue may also influence therapeutic efficacy and clinical outcomes. Intrathoracic chemotherapy plays a role not only in the treatment of primary MPM, but can be extended to treatment of secondary pleural metastases and resulting MPE as well as extensive thymic cancer. The spread of malignant cells into the pleura leads to increased production of pleural fluid accompanied by reduced absorption of fluids and thus to MPE (31-33). MPE itself has been shown to accelerate tumour growth and dissemination, as well as contribute to chemoresistance. The high concentration of growth mediators in MPE leads to consistently stimulated cell proliferation and induced cell migration (34,35). MPE is not only generally associated with a low life expectancy of three to twelve months, but also with a significantly reduced quality of life due to symptoms such as dyspnea, coughing and chest pain (31,32,35). It affects over 90% of patients with MM and occurs in over 15% of all malignant diseases (36). Consequently, effective management of MPE remains a crucial component of both symptom control and tumour containment strategies. Current Treatment options include ultrasound-guided pleural paracentesis, indwelling pleural catheters, and chemical pleurodesis (33). However, not only do these procedures carry the risk of complications such as chest pain, pneumonia, empyema, pneumothorax, catheter related infections, and tract seeding of malignant cells, but 90% of patients also require re-intervention and hospitalisation. HITOC has been used in the treatment of MPE, yet with symptom control rates ranging between 59–88%, it has shown inferior outcomes compared to other surgical modalities (37,38). Overall, the treatment options available to date are unsatisfactory in terms of both efficacy and tolerability. Based on the positive PIPAC outcomes in the treatment of peritoneal metastases, PITAC has been investigated as a potential alternative for managing MPE. While initial studies have demonstrated the technical feasibility of the procedure, robust evidence regarding its symptomatic and oncological efficacy in MPE remains limited (10,12,39). Our study suggests that PITAC achieves higher tissue penetration and staining intensity than HITOC in an ex vivo porcine model, primarily due to its ability to deliver higher local drug concentrations through minimal total volumes. Given that concentration emerged as the dominant variable influencing efficacy, this pharmacokinetic advantage suggests a potential advantage of PITAC for intrathoracic drug delivery. However, these findings must be interpreted in the context of several limitations inherent to the present experimental design. Physiological factors present in vivo, such as blood circulation, lymphatic drainage, respiratory motion and negative intrathoracic pressure, are absent in this model and may influence drug distribution and clearance. In addition, aerosol behaviour within a static experimental chamber may differ from distribution patterns in the clinical thoracic cavity, where anatomical structures and respiratory movement may lead to heterogeneous drug exposure. Another limitation of this study is that only cisplatin was evaluated. However, cisplatin represents the most commonly used chemotherapeutic agent in intrathoracic chemotherapy protocols for MPM. Furthermore, the immunohistochemical detection method applied in this study specifically identifies cisplatin-induced DNA adducts, which necessitated the use of this agent in the present experimental setup. Consequently, the observed penetration characteristics cannot be directly extrapolated to clinical outcomes, and further in vivo and clinical studies are required to determine whether the pharmacological advantages observed in this model translate into clinical benefit. Conclusions In summary, our study demonstrates that PITAC is technically feasible and shows favourable penetration characteristics compared to HITOC in an ex vivo model. Whether these findings translate into improved clinical outcomes in the treatment of MPM, secondary pleural metastases and MPE requires further investigation. PITAC may represent a promising alternative to HITOC, which is technically more demanding. Supplementary The article’s supplementary files as Acknowledgments We would like to thank Ernst Gehrke (Hannoverimpuls GmbH) and Jens Abel (Pharma Resources Hameln) for their kind support with this project. Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The original animal procedures and organ explant procurement were approved by the Lower Saxony State Office for Consumer Protection and Food Safety (LAVES; Niedersächsisches Landesamt für Verbraucherschutz und Lebensmittelsicherheit) under approval number 21/3782. Since only post-mortem tissue samples were used in the present ex vivo study, no additional ethical approval was required for the present experiments. Footnotes Reporting Checklist: The authors have completed the ARRIVE reporting checklist. Available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-1-0258/rc Funding: This study was supported by a research grant awarded by the Lower Saxony innovation Program for Research and development in Companies (Niedersächsisches Förderinnovationsprogramm für Forschung und Entwicklung in Unternehmen, NIFEP). Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-1-0258/coif). All authors report that this project was kindly supported by a research grant awarded by the Lower Saxony innovation Program for Research and development in Companies (Niedersächsisches Förderinnovationsprogramm für Forschung und Entwicklung in Unternehmen, NIFEP). The authors have no other conflicts of interest to declare. Data Sharing Statement Available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-1-0258/dss References Available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-1-0258/prf Supplementary Materials The article’s supplementary files as Data Availability Statement Available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-1-0258/dss